A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 443 participants.

Also called NCT03861039

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 443 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03861039
Other papers using this trial's data
  • Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial The lancet. Diabetes & endocrinology, 2022-09 DOI, PubMed 35914542

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03861039. Randomized; no masking; primary purpose treatment. Start 2019-03-30 (actual); primary completion 2021-01-26 (actual). Results posted on 2022-02-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Oral antihyperglycemic medication (OAM)
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03861039
Content hash
06fadafa7c7720d50ebf5ba1eb3d008d9b8c05eb8dacc07300aa37a590ddf00c